Literature DB >> 20727938

Intracerebroventricular injection of orexin-A stimulates monoamine metabolism but not HPA axis in neonatal chicks.

Sachiko Katayama1, Kazutaka Shigemi, Mark A Cline, Mitsuhiro Furuse.   

Abstract

We investigated the effects of intracerebroventricular (ICV) injection of orexin-A on plasma corticosterone (CORT) concentration and brain monoamine metabolism to clarify the mechanism by which ICV orexin-A induced arousal in chicks. In Experiment 1, plasma CORT concentrations were measured as an indicator of hypothalamic-pituitary-adrenal (HPA) axis activity. There was no significant difference in CORT concentration between the control and orexin-A administered groups. In Experiment 2, the concentrations of monoamines (norepinephrine, dopamine and serotonin), their metabolites, and their metabolic turnover rates in the telencephalon, mesencephalon, and diencephalon were investigated. All metabolic turnover rates studied were increased at all brain sites after ICV orexin-A injection. In conclusion, the HPA axis does not appear to be involved in arousal-inducing mechanisms of orexin-A in neonatal chicks; however, several monoaminergic systems do.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20727938     DOI: 10.1016/j.neulet.2010.08.043

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  2 in total

1.  Hypothalamic orexin--a neurons are involved in the response of the brain stress system to morphine withdrawal.

Authors:  M Luisa Laorden; Szilamér Ferenczi; Bernadett Pintér-Kübler; Laura L González-Martín; M Carmen Lasheras; Krisztina J Kovács; M Victoria Milanés; Cristina Núñez
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

2.  Early expression of hypocretin/orexin in the chick embryo brain.

Authors:  Kyle E Godden; Jeremy P Landry; Natalya Slepneva; Paola V Migues; Maria Pompeiano
Journal:  PLoS One       Date:  2014-09-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.